RIGEL PHARMACEUTICALS INC
RIGL evidence brief
What we can confirm
- BioSniper Score:
- 7.4 / 10
- Market Cap:
- $874.8M
- Lead Asset:
- gavreto (Approved)
What it means
What to watch
Prepared research question
What matters most for RIGL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RIGL
Rigel Pharmaceuticals Inc. is a commercial-stage biotechnology company focused on hematologic disorders and cancer, with four approved products (TAVALISSE, GAVRETO, REZLIDHIA, VEPPANU) and a clinical-stage pipeline including R289 for lower-risk MDS.
Key risk: Modest cash runway
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 4 clinical trials · 3 catalysts · 4 FDA decisions for RIGEL PHARMACEUTICALS INC.
Rigel Pharmaceuticals Inc. is a commercial-stage biotechnology company focused on hematologic disorders and cancer, with four approved products (TAVALISSE, GAVRETO, REZLIDHIA, VEPPANU) and a clinical-stage pipeline including R289 for lower-risk MDS.
- As of June 30, 2026, Rigel reported cash & equivalents of $60.8M, total revenue of $78.7M, net income of $17.3M, shareholders' equity of $425.4M, and total debt of $40.0M [sec].
- The company markets four approved drugs: TAVALISSE (fostamatinib), GAVRETO (pralsetinib), REZLIDHIA (olutasidenib), and VEPPANU (vepdegestrant) [news · published 2026-08-04].
- R289, an IRAK1/4 inhibitor, is in Phase 1/2 for lower-risk myelodysplastic syndromes (MDS) and has received Fast Track and Orphan Drug designations [pipeline].
- GAVRETO (pralsetinib) is approved for metastatic RET fusion-positive NSCLC and thyroid cancer, with final ARROW study data published in the Journal of Clinical Oncology in March 2026 [news · published 2026-03-31].
- VEPPANU (vepdegestrant), a PROTAC drug for ESR1m ER+/HER2- advanced breast cancer, was approved by the FDA in May 2026 and in-licensed by Rigel for exclusive global rights [news · published 2026-05-12].
What works
- Rigel has four approved commercial products generating revenue, including TAVALISSE, GAVRETO, REZLIDHIA, and the newly approved VEPPANU, providing a diversified revenue base [news · published 2026-08-04].
- The company achieved net income of $17.3M in the latest reported quarter (Q2 2026), indicating profitability [sec].
- R289 has Fast Track and Orphan Drug designations for lower-risk MDS, which may expedite development and provide market exclusivity if approved [pipeline].
- VEPPANU targets a $1B market opportunity for ESR1m ER+/HER2- advanced breast cancer, with FDA approval already secured [news · published 2026-08-05].
What to weigh
- Rigel's cash position of $60.8M as of June 30, 2026, is relatively modest and may require additional financing to support pipeline development and commercialization [sec].
- The company faces competition for GAVRETO from Lilly's selpercatinib and other therapies, which could limit market share [pipeline].
- R289 is still in early-stage clinical development (Phase 1/2) for lower-risk MDS, with no guarantee of successful completion or regulatory approval [pipeline].
- Patent expirations for fostamatinib (2032), olutasidenib (2039), and pralsetinib (2042) could eventually expose revenue to generic competition [catalyst].
From the filings
Quoted directly from source documents.
Rigel reported Q2 2026 financial results including sales of TAVALISSE, GAVRETO, and REZLIDHIA.
“Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2026, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress, including the in-license of VEPPANU™ (vepdegestrant), a PRoteolysis TArgeting Chimera (PROTAC).”
News · August 4, 2026
VEPPANU was approved by the FDA for ESR1m ER+/HER2- advanced breast cancer.
“Announced FDA Approval of VEPPANU™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer”
News · May 12, 2026
R289 is an IRAK1/4 inhibitor in Phase 1/2 for lower-risk MDS.
“Pipeline Candidate: r289 Indication: lower-risk myelodysplastic syndrome (MDS) Phase: Phase 1/Phase 2 Mechanism of Action: interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor”
GAVRETO final ARROW study data was published in the Journal of Clinical Oncology.
“Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2 ARROW study evaluating pralsetinib for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) in the Journal of Clinical Oncology.”
News · March 31, 2026
Catalyst timeline
- 2032-07-27 · Patent_Expiry · FOSTAMATINIB DISODIUM — Patent_Expiry: NDA209299 — Expiry of the patent covering fostamatinib (TAVALISSE), which could allow generic competition.
- 2039-11-12 · Patent_Expiry · OLUTASIDENIB — Patent_Expiry: NDA215814 — Expiry of the patent covering olutasidenib (REZLIDHIA), potentially opening the market to generics.
- 2042-07-07 · Patent_Expiry · PRALSETINIB — Patent_Expiry: NDA213721 — Expiry of the patent covering pralsetinib (GAVRETO), which may lead to generic entry.
Risks & what to watch (4)›
Key risks
- Modest cash runway — Cash of $60.8M as of June 30, 2026, may require future financing to fund operations and pipeline [sec].
- Competition for GAVRETO — GAVRETO faces competition from Lilly's selpercatinib and other therapies in RET+ NSCLC and thyroid cancer [pipeline].
- Early-stage pipeline risk — R289 is in Phase 1/2 for lower-risk MDS; clinical failure or regulatory delays are possible [pipeline].
- Patent expirations — Key patents for fostamatinib (2032), olutasidenib (2039), and pralsetinib (2042) will eventually expire [catalyst].
What to watch
- R289 Phase 1/2 data readout for lower-risk MDS, a key 2026 catalyst [news · published 2026-01-26].
- Commercial uptake of VEPPANU following FDA approval in May 2026 [news · published 2026-05-12].
- Revenue trends from TAVALISSE, GAVRETO, and REZLIDHIA in upcoming quarterly reports [news · published 2026-08-04].
- Potential partnership or financing activities to support pipeline and cash position [sec].
Sources: Catalysts · News · Pipeline · Generated October 3, 2026 · How we verify sources →
Run RIGEL PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RIGEL PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.22 · 6% dilution
Lead: Approved
5 candidates
3 upcoming, next in ~2113d
0 buys · 2 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 21.8%
- Days to cover
- 11.6
- Shares short
- 3,935,324
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RIGL short interestGovernance
Frequently asked questions
What is the AI investment thesis for RIGEL PHARMACEUTICALS INC?
Rigel Pharmaceuticals Inc. is a commercial-stage biotechnology company focused on hematologic disorders and cancer, with four approved products (TAVALISSE, GAVRETO, REZLIDHIA, VEPPANU) and a clinical-stage pipeline including R289 for lower-risk MDS.
What is RIGEL PHARMACEUTICALS INC's lead drug candidate?
RIGEL PHARMACEUTICALS INC's most advanced tracked candidate is gavreto (Approved) for metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and advanced or metastatic RET fusion-positive thyroid cancer.
What is RIGEL PHARMACEUTICALS INC's next catalyst?
RIGEL PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA209299" — expected July 27, 2032.
Who is the CEO of RIGEL PHARMACEUTICALS INC?
Mr. Raul R. Rodriguez is the chief executive officer of RIGEL PHARMACEUTICALS INC (RIGL).
Where is RIGEL PHARMACEUTICALS INC headquartered?
RIGEL PHARMACEUTICALS INC (RIGL) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.